期刊
OPEN FORUM INFECTIOUS DISEASES
卷 7, 期 5, 页码 -出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofaa150
关键词
Acinetobacter baumannii; antimicrobial resistance; cefiderocol; osteomyelitis
资金
- National Institutes of Health [K24-AI093969]
- MedImmune
- Cerexa/Forest/Actavis/Allergan
- Pfizer
- Advanced Liquid Logics
- Theravance
- Novartis
- Cubist/Merck
- Medical Biosurfaces
- Locus
- Affinergy
- Contrafect
- Karius
- Genentech
- Regeneron
- Basilea
Cefiderocol is a novel catechol siderophore cephalosporin antibiotic developed to treat resistant gram-negative infections. We describe its successful use as rescue therapy, combined with surgical debridement, to treat a patient with osteomyelitis due to extensively drug-resistant Acinetobacter baumannii. Bacterial whole-genome sequencing identified the strain and antibiotic resistance determinants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据